What is Kura Oncology Inc Annual Net Profit?

Kura Oncology Inc Annual Net Profit fell 13.99% in the last year to $173.98 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

What is Kura Oncology Inc Price to Earning Ratio?

Kura Oncology Inc Price to Earning Ratio is -2.91, which is negative.

What is Kura Oncology Inc Stock Price?

Kura Oncology Inc Stock Price fell 64.29% and underperformed its sector by 71.65% in the past year.

What is Kura Oncology Inc Quarterly Net profit?

Kura Oncology Inc Quarterly Net profit rose 55.09% YoY to $19.22 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

What is Kura Oncology Inc Debt to Equity Ratio?

Kura Oncology Inc Debt to Equity Ratio of 0.04 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Kura Oncology Inc Return on Equity(ROE)?

Kura Oncology Inc Return on Equity(ROE) for the last financial year was -42.91%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Kura Oncology Inc Mutual Fund Holding?

Kura Oncology Inc Mutual Fund Holding decreased by 2.33% in the last quarter to 35.66.

What is Kura Oncology Inc Promoter Share Holding?

Kura Oncology Inc Promoter Share Holding increased by 0.56% in the most recent quarter to 0.9%.

What is Kura Oncology Inc Interest Coverage Ratio?

Kura Oncology Inc Interest Coverage Ratio is -105.22, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Kura Oncology Inc Institutional Holding?

Kura Oncology Inc Institutional Holding increased by 0.02% in the last quarter to 99.09.

How is the Kura Oncology Inc today?

The Kura Oncology Inc today is trading in the green, up by 6.10% at 6.26.

How has Kura Oncology Inc performed historically?

The Kura Oncology Inc is currently trading up 6.10% on an intraday basis in the past week the index rose 8.49%. The index has been down -13.77% in the past quarter and fell -64.29% in the past year. You can view this in the overview section.

Kura Oncology Inc XNAS: KURA

Kura Oncology Inc Live Share Price Today, Share Analysis and Chart

Name: Kura Oncology Inc: Is Infosys Ltd. worth buying?
Item: Kura Oncology Inc
Rating: 1.3778195
Author: Trendlyne DVM scores

Weak Stock

Download real time

6.26 0.36 (6.10%)

73.34% Fall from 52W High

130.4K XNAS Volume

XNAS 21 Apr, 2025 11:12 AM (EDT)

Kura Oncology Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	505.7
PE TTM Negative PE TTM Unavailable in chosen country	-2.9
PEG TTM High in industry Unavailable in chosen country	0.2
Price to Book Below industry Median Unavailable in chosen country	1.2
Institutional holding current Qtr % High in industry Unavailable in chosen country	99.1
Net Profit Qtr Growth YoY % High in industry Unavailable in chosen country	55.1
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-14
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-41.7
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-358.5
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-13.6
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-42.9
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-28.8

All financials are in USD Million and price data in USD

Low Financial Strength

27.8 / 100

Mid Valuation

30.5 / 100

Technically Bearish

24.2 / 100

Weak Stock These stocks are the ones with poor quality and weak financial and technical aspects. However, these stocks have a medium valuation score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 347%

12 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Kura Oncology Inc Stock Price Analysis

Day Price Range 6.1% 1 Day return Unavailable in chosen country	6.3 (LTP) 5.86.3 LowHigh
Week Price Range 8.5% 1 Week return Unavailable in chosen country	6.3 (LTP) 5.66.3 LowHigh
Month Price Range -20.2% 1 Month return Unavailable in chosen country	6.3 (LTP) 5.48 LowHigh
52 Week Price Range -64.3% 1 Year return Unavailable in chosen country	6.3 (LTP) 5.423.5 LowHigh

View full Share Price History

Kura Oncology Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

Kura Oncology Inc's Revenue was lower than average estimate 1 time in past 1 year

EPS forecast

QUARTER
ANNUAL

Current EPS

-2

Avg. Estimate

-2

Low Estimate

-3.3

High Estimate

-0.3

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 3.0% in FY25

Consensus Recommendation

15 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 15 analysts for Kura Oncology Inc is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Kura Oncology Inc Stock Analysis

Kura Oncology Inc stock analysis with key metrics, changes, and trends.

Kura Oncology Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$173.98 M	13.99%	negative	Annual Net Profit fell 13.99% in the last year to $173.98 M. Its sector's average net profit growth for the last fiscal year was -30.36%.
Price to Earning Ratio	-2.91	-	negative	Price to Earning Ratio is -2.91, which is negative.
Stock Price	$6.26	-64.29%	negative	Stock Price fell 64.29% and underperformed its sector by 71.65% in the past year.
Quarterly Net profit	$19.22 M	55.09%	positive	Quarterly Net profit rose 55.09% YoY to $19.22 M. Its sector's average net profit growth YoY for the quarter was -48.37%.
Debt to Equity Ratio	0.04	-	positive	Debt to Equity Ratio of 0.04 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-42.91 %	-42.91%	negative	Return on Equity(ROE) for the last financial year was -42.91%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	35.66 %	-2.33%	negative	Mutual Fund Holding decreased by 2.33% in the last quarter to 35.66.
Promoter Share Holding	0.90 %	0.56%	positive	Promoter Share Holding increased by 0.56% in the most recent quarter to 0.9%.
Interest Coverage Ratio	-105.22	-	negative	Interest Coverage Ratio is -105.22, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	99.09 %	0.02%	positive	Institutional Holding increased by 0.02% in the last quarter to 99.09.

VIEW LESS

Loading data..

Kura Oncology Inc - Company Profile

What does Kura Oncology Inc do?

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

393.57 K

2024

Gross Remuneration

Year

Kura Oncology Inc Live Share Price Today, Share Analysis and Chart

73.34% Fall from 52W High

Kura Oncology Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

RoA Annual %

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Kura Oncology Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Kura Oncology Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Kura Oncology Inc's Revenue was lower than average estimate 1 time in past 1 year

EPS forecast

EPS is expected to grow by 3.0% in FY25

Consensus Recommendation

The consensus recommendation from 15 analysts for Kura Oncology Inc is STRONG BUY

Kura Oncology Inc Stock Analysis

Kura Oncology Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 13.99% in the last year to $173.98 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio is -2.91, which is negative.

Stock Price fell 64.29% and underperformed its sector by 71.65% in the past year.

Quarterly Net profit rose 55.09% YoY to $19.22 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Debt to Equity Ratio of 0.04 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -42.91%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 2.33% in the last quarter to 35.66.

Promoter Share Holding increased by 0.56% in the most recent quarter to 0.9%.

Interest Coverage Ratio is -105.22, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding increased by 0.02% in the last quarter to 99.09.

Kura Oncology Inc - Company Profile

What does Kura Oncology Inc do?

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Kura Oncology Inc Management structure

Mr. Stephen Dale

Chief Medical Officer

Dr. Mollie Leoni, M.D.

Chief Medical Officer

Mr. Francis Burrows, PhD

Chief Scientific Officer

Kura Oncology Inc Board of directors

Dr. Michael J. Vasconcelles, M.D.

Independent Director

Mr. Faheem Hasnain

Lead Independent Director

Ms. Carol A. Schafer

Independent Director

Ms. Mary T. Szela

Independent Director

Mr. Thomas R. Malley

Independent Director

Dr. Helen Collins, M.D.

Independent Director